Bladder cancer
Open
Phase 1/2
This study is looking at sacituzumab tirumotecan for non muscle invasive bladder cancer.
It is open to people with non muscle invasive bladder cancer that is and has come back after treatment.
Sacituzumab tirumotecan is also called sac-TMT and MK-2870.
You pronounce sacituzumab tirumotecan as sass-ih-too-zo-mab tie-rum-o-tee-can.
Recruitment start: 6 August 2025
Recruitment end: 30 June 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Szabados
Merck Sharp & Dohme Ltd
Last reviewed: 09 Jan 2026
CRUK internal database number: 20025
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
